Clinicopathological differences in patients with hilar bile duct carcinoma and intrahepatic cholangiocarcinoma involving the hepatic hilum

• Published in: Tando Vol. 20; no. 2; pp. 128 - 134
• Main Authors: RONDO, Kazuhiro, CHIJIIWA, Kazuo, KAI, Masahiro, OHUCHIDA, Jiro, MAEHARA, Naoki
• Format: Journal Article
• Language: Japanese
• Published: Japan Biliary Association 2006
• Subjects: cilnicopathological differences; hilar bile duct carcinoma; intrahepatic cholangiocarcinoma
• ISSN: 0914-0077; 1883-6879
• DOI: 10.11210/tando1987.20.2_128

Clinicopathological differences in hilar bile duct carcinoma (HBDCa) and intrahepatic cholangiocarcinoma involving the hepatic hilum (ICCaH) were compared to examine the treatment strategy and possible application of the same classification system for these carcinomas. The patients who had undergone curative resection for HBDCa (n=16, group A) and those for ICCaH (n=12, group B) in our department were the basis of this study. In the group A, the size of tumor was significantly smaller and jaundice was more frequent than those in group B. The hepatic hilum was the dominant site of recurrence in group A whereas was the remnant liver in group B. Postoperative survival rates were not different between the two groups. The significant prognostic factors were portal vein invasion and lymph nodes metastasis in group B, while no factor was found in group A. Based on these results, more extended hepatectomy combined with vascular resection and reconstruction is the choice of treatment for group A, while postoperative adjuvant chemotherapy should be added to improve the result in group B. The differences in prognostic factors and recurrence sites suggest that HBDCa and ICCaH should be classified by the different system.